$SPRO

3 theses

bullish 100%neutral 0%bearish 0%

Avg return (1y)

—

Win rate (1y)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Oct 26, 4:15 PM ET

$SPROr/pennystocksGeneral Discussionbullish

u/GeneralZello · 102d ago3 prior · 25% at 3mo

Long 11,000 shares of SPRO

SPRO Spero Therapeutics FDA approval and then drops? Cheaper buyout?

SPRO is undervalued following FDA approval of Utebzi (marketed via GSK partnership with estimated $1B+ sales potential) and a $1.1B milestone deal for SP001. Despite strong catalysts, the stock has declined post-approval, making it a buyout candidate trading well below intrinsic value.

At post $1.16Now $1.07-7.8% since postedas of Oct 26, 4:15 PM ET

1d+2.6%

3d+2.6%

1w+3.4%

1m+5.2%

3m+0.9%

6m—

1y—

original post →

$SPROr/pennystocksGeneral Discussionbullish

u/Weekly-Barracuda-494 · 111d ago1 prior · 0% at 3mo

Spero Therapeutics Changing focus

Spero Therapeutics monetized GSK royalty payments to fund a pivot toward developing an antibody asset from Innovent Biologics, with up to $326M in GSK milestone payments and enough capital to run Phase 2/3 trials without dilution, positioning the company for potential upside if the new asset succeeds clinically.

At post $1.70Now $1.07-37.1% since postedas of Oct 26, 4:15 PM ET

1d0.0%

3d-7.1%

1w-18.8%

1m-27.1%

3m-30.6%

6m—

1y—

original post →

$SPROr/pennystocksDDbullish

u/BioIsLife_PortIsDead · 147d agono track record yet

“Buy shares along with a few $2.5 puts as insurance for a CRL. July $2.5 calls with some puts as a hedge.”

SPRO - 50 Shades of Green

Tebipenem, SPRO's first oral carbapenem for complicated UTIs, has Phase 3 data backed by FDA-agreed SPA, stopped early for overwhelming efficacy, and is expected to secure approval with high confidence. Post-approval, GSK handles commercialization while SPRO collects guaranteed $101M milestones plus sales-based payments and royalties, making execution risk low and upside potential substantial.

At post $2.57Now $1.07-58.4% since postedas of Oct 26, 4:15 PM ET

1d-1.2%

3d+10.9%

1w+7.8%

1m-17.5%

3m-52.9%

6m—

1y—

original post →

End of results.